OTCPK:TIKR.F

Stock Analysis Report

Executive Summary

Tikcro Technologies Ltd. focuses on an early stage biotechnology project in Israel.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Tikcro Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TIKR.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

45.0%

TIKR.F

0.7%

US Biotechs

-1.1%

US Market


1 Year Return

52.4%

TIKR.F

14.0%

US Biotechs

17.9%

US Market

Return vs Industry: TIKR.F exceeded the US Biotechs industry which returned 14% over the past year.

Return vs Market: TIKR.F exceeded the US Market which returned 17.9% over the past year.


Shareholder returns

TIKR.FIndustryMarket
7 Day45.0%0.7%-1.1%
30 Day81.1%5.6%1.4%
90 Day16.0%6.2%6.9%
1 Year52.4%52.4%14.9%14.0%20.3%17.9%
3 Year-12.2%-12.2%24.4%21.1%47.8%38.3%
5 Year-54.7%-54.7%3.8%-1.0%71.9%53.0%

Price Volatility Vs. Market

How volatile is Tikcro Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Tikcro Technologies undervalued compared to its fair value and its price relative to the market?

0.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TIKR.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TIKR.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TIKR.F is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: TIKR.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TIKR.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TIKR.F is good value based on its PB Ratio (0.7x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Tikcro Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tikcro Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Tikcro Technologies performed over the past 5 years?

-9.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TIKR.F is currently unprofitable.

Growing Profit Margin: TIKR.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TIKR.F is unprofitable, and losses have increased over the past 5 years at a rate of -9.7% per year.

Accelerating Growth: Unable to compare TIKR.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TIKR.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: TIKR.F has a negative Return on Equity (-26.78%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Tikcro Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: TIKR.F's short term assets ($4.6M) exceed its short term liabilities ($264.0K).

Long Term Liabilities: TIKR.F has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: TIKR.F is debt free.

Reducing Debt: TIKR.F has not had any debt for past 5 years.


Balance Sheet

Inventory Level: TIKR.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: TIKR.F's debt is not covered by short term assets (assets are -68x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if TIKR.F has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TIKR.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Tikcro Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate TIKR.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TIKR.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TIKR.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TIKR.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TIKR.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average board tenure


CEO

Aviv Boim (51yo)

9.3yrs

Tenure

US$339,000

Compensation

Mr. Aviv Boim has been the Chief Executive Officer of Tikcro Technologies Ltd. since November 2010. Mr. Boim served as the Chief Financial Officer and General Manager of Israel of Imperva Inc. since Septem ...


CEO Compensation Analysis

Compensation vs Market: Aviv's total compensation ($USD339.00K) is below average for companies of similar size in the US market ($USD522.48K).

Compensation vs Earnings: Aviv's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Eric Paneth
Director20.1yrsUS$11.00k11.71% $335.3k
Rami Skaliter
External Director4.1yrsUS$21.00kno data
Izhak Tamir
Chairman of the Board20.1yrsUS$15.00k10.75% $307.8k
Shlomzion Shen
External Director1.1yrsno datano data
Dror Melamed
Independent Director1.1yrsno datano data

4.1yrs

Average Tenure

61yo

Average Age

Experienced Board: TIKR.F's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Tikcro Technologies Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tikcro Technologies Ltd.
  • Ticker: TIKR.F
  • Exchange: OTCPK
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.864m
  • Shares outstanding: 9.88m
  • Website: https://www.tikcro.com

Number of Employees


Location

  • Tikcro Technologies Ltd.
  • 7 Sapir Street
  • 5th Floor
  • Ness Ziona
  • 7403630
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TIKR.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2000

Biography

Tikcro Technologies Ltd. focuses on an early stage biotechnology project in Israel. The company engages in the development of anti-cytotoxic T-lymphocyte-associated protein 4 and antibodies selected and verified in pre-clinical trials with a focus on antibodies targeting immune modulator pathways for cancer treatment. The company was formerly known as Tioga Technologies Ltd. and changed its name to Tikcro Technologies Ltd. in September 2003. Tikcro Technologies Ltd. was founded in 1999 and is headquartered in Ness Ziona, Israel. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 00:15
End of Day Share Price2020/02/18 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.